An international consortium of clinicians reports the results of a phase III open-label trial designed to assess the benefit and tolerability of a monoclonal antibody, rozanolixizumab, administered by the patient either by manual pressure or via an infusion pump:
- 62 adults with generalised myasthenia gravis participated in the trial and were divided into two groups, with a crossover period.
- The trial lasted a total of 18 weeks, with the usual efficacy and safety criteria being used.
- 100% of patients were successful with this alternative method and 63% preferred to be able to control it themselves (by manual pressure).
As well tolerated as in a hospital setting and as effective in terms of clinical parameters, this alternative method of home administration could eventually become the norm for a larger number of patients.
